Genrix grossed $478.9m in the largest initial public offering from an innovative drug-focused biotech on Shanghai's STAR Market since February 2022. Meanwhile, Laekna and Cutia launched two smaller IPOs in Hong Kong.

The divestiture is part of BD’s ongoing plan to cut 20% of its total product portfolio by 2025.

While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.